Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo

Archives of Toxicology

Volumn 90, Issue 1, 2016, Pages 203-215

  Bonifacio, Annalisa ^a,b   Mullen, Peter J ^a,b   Mityko, Ileana Scurtu ^a,b   Navegantes, Luiz C ^c   Bouitbir, Jamal ^a,b,d   Krähenbühl, Stephan ^a,b,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Swiss Centre for Applied Human Toxicology   (Switzerland)

Author keywords

Apoptosis; Atrogin 1; FoxO transcription factors; Mitochondrial respiration; Simvastatin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ATROGIN 1; MESSENGER RNA; SIMVASTATIN; TRANSCRIPTION FACTOR FKHRL1; FBXO32 PROTEIN, MOUSE; FBXO32 PROTEIN, RAT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3A PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MULTIENZYME COMPLEX; MUSCLE PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART WEIGHT; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY CHAIN; UPREGULATION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; ENZYME ACTIVATION; HEART MITOCHONDRION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RAT; TIME FACTOR;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CARDIOTOXICITY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENERGY METABOLISM; ENZYME ACTIVATION; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MUSCLE PROTEINS; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; SIMVASTATIN; SKP CULLIN F-BOX PROTEIN LIGASES; TIME FACTORS; UP-REGULATION;

EID: 84955380617     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1378-4     Document Type: Article

References (48)

1. Adams V, Linke A, Wisloff U et al (2007) Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res 73(1):120–129. doi:10.1016/j.cardiores.2006.10.026
2. Alfazari AS, Al-Dabbagh B, Almarzooqi S, Albawardi A, Souid AK (2013) Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin. BMC Pharmacol Toxicol 14:15. doi:10.1186/2050-6511-14-15
3. Amarenco P, Bogousslavsky J, Callahan A III et al (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6):549–559. doi:10.1056/NEJMoa061894
4. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I (2006) Bistability in apoptosis: roles of Bax, Bcl-2, and mitochondrial permeability transition pores. Biophys J 90(5):1546–1559. doi:10.1529/Biophysj.105.068122
5. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J (2001) HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132(6):1183–1192. doi:10.1038/sj.bjp.0703920
6. Bouitbir J, Charles AL, Echaniz-Laguna A et al (2012) Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J 33(11):1397–1407. doi:10.1093/eurheartj/ehr224
7. Bursac N, Papadaki M, Cohen RJ et al (1999) Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies. Am J Physiol 277(2 Pt 2):H433–H444
8. Cao P, Hanai J, Tanksale P, Imamura S, Sukhatme VP, Lecker SH (2009) Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 23(9):2844–2854. doi:10.1096/fj.08-128843
9. Chiacchiera F, Simone C (2010) The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 9(6):1091–1096
10. Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(23 Suppl 1):III39–III43. doi:10.1161/01.CIR.0000131517.20177.5a
11. Demyanets S, Kaun C, Pfaffenberger S et al (2006) Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol 71(9):1324–1330. doi:10.1016/j.bcp.2006.01.016
12. Felser A, Blum K, Lindinger PW, Bouitbir J, Krahenbuhl S (2013) Mechanisms of hepatocellular toxicity associated with dronedarone—a comparison to amiodarone. Toxicol Sci 131(2):480–490. doi:10.1093/toxsci/kfs298
13. Graham DJ, Staffa JA, Shatin D et al (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585–2590. doi:10.1001/jama.292.21.2585
14. Group SS (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389
15. Hanai J, Cao P, Tanksale P et al (2007) The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117(12):3940–3951. doi:10.1172/jci32741
16. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13(4):251–262. doi:10.1038/Nrm3311
17. Joy TR, Hegele RA (2009) Narrative review: statin-related myopathy. Ann Intern Med 150(12):858–868
18. Kang BY, Wang W, Palade P, Sharma SG, Mehta JL (2009) Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 54(4):327–334. doi:10.1097/FJC.0b013e3181b76713
19. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S (2006) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63(19–20):2415–2425. doi:10.1007/s00018-006-6235-z
20. Kong JY, Rabkin SW (2004) Cytoskeletal actin degradation induced by lovastatin in cardiomyocytes is mediated through caspase-2. Cell Biol Int 28(11):781–790. doi:10.1016/j.cellbi.2004.07.012
21. Kwak HB, Thalacker-Mercer A, Anderson EJ et al (2012) Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 52(1):198–207. doi:10.1016/j.freeradbiomed.2011.10.449
22. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425–1435. doi:10.1056/NEJMoa050461
23. Larsen S, Stride N, Hey-Mogensen M et al (2013) Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 61(1):44–53. doi:10.1016/j.jacc.2012.09.036
24. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC (2007) Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther 321(2):626–634. doi:10.1124/jpet.106.118331
25. Link E, Parish S, Armitage J et al (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799. doi:10.1056/NEJMoa0801936
26. Matzno S, Yasuda S, Juman S et al (2005) Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 57(11):1475–1484. doi:10.1211/jpp.57.11.0014
27. Mearini G, Gedicke C, Schlossarek S et al (2010) Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res 85(2):357–366. doi:10.1093/cvr/cvp348
28. Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13(9):1016–1023. doi:10.1038/ncb2329
29. Mohler ER III, Hiatt WR, Creager MA (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108(12):1481–1486. doi:10.1161/01.cir.0000090686.57897.f5
30. Mullen PJ, Luscher B, Scharnagl H, Krahenbuhl S, Brecht K (2010) Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol 79(8):1200–1209. doi:10.1016/j.bcp.2009.12.007
31. Mullen PJ, Zahno A, Lindinger P et al (2011) Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta 1813(12):2079–2087. doi:10.1016/j.bbamcr.2011.07.019
32. Perlman H, Zhang XJ, Chen MW, Walsh K, Buttyan R (1999) An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 6(1):48–54. doi:10.1038/Sj.Cdd.4400453
33. Rabkin SW, Kong JY (2003) Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol 193(3):346–355
34. Rabkin SW, Lodha P, Kong JY (2007) Reduction of protein synthesis and statin-induced cardiomyocyte cell death. Cardiovasc Toxicol 7(1):1–9. doi:10.1007/s12012-007-0003-7
35. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263–275
36. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659–661. doi:10.1096/fj.07-9574LSF
37. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195–2207. doi:10.1056/NEJMoa0807646
38. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG (2004) Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38(6):978–981. doi:10.1345/aph.1D498
39. Sakamoto K, Wada I, Kimura J (2011) Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin’s toxicity in rat skeletal myofibers. J Pharmacol Exp Ther 338(1):62–69. doi:10.1124/jpet.111.179762
40. Sandri M, Sandri C, Gilbert A et al (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117(3):399–412
41. Schick BA, Laaksonen R, Frohlich JJ et al (2007) Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 81(5):650–653. doi:10.1038/sj.clpt.6100124
42. Singh R, Krishan P (2010) Modulation of impact of high fat diet in pathological and physiological left ventricular cardiac hypertrophy by fluvastatin. Biomed Pharmacother 64(3):147–153. doi:10.1016/j.biopha.2009.06.016
43. Sirvent P, Bordenave S, Vermaelen M et al (2005) Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun 338(3):1426–1434. doi:10.1016/j.bbrc.2005.10.108
44. Sirvent P, Fabre O, Bordenave S et al (2012) Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 259(2):263–268. doi:10.1016/j.taap.2012.01.008
45. Thorpe JL, Doitsidou M, Ho SY, Raz E, Farber SA (2004) Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation. Dev Cell 6(2):295–302
46. Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100(3):328–341. doi:10.1161/01.Res.0000256090.42690.05
47. Tuckow AP, Jefferson SJ, Kimball SR, Jefferson LS (2011) Simvastatin represses protein synthesis in the muscle-derived C(2)C(1)(2) cell line with a concomitant reduction in eukaryotic initiation factor 2B expression. Am J Physiol Endocrinol Metab 300(3):E564–E570. doi:10.1152/ajpendo.00383.2010
48. Vander Heiden MG, Thompson CB (1999) Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1(8):E209–E216. doi:10.1038/70237